EcoDrugPlus

Cholinergic Receptor, Muscarinic 2a

Ensembl ID : ENSOMYG00000016204
Gene Symbol: CHRM2A
1 Cross references
189 Possible Orthologues:

Cholinergic Receptor, Muscarinic 2a

Ensembl ID : ENSOMYG00000014370
Gene Symbol: CHRM2A
1 Cross references
190 Possible Orthologues:

Cholinergic Receptor, Muscarinic 5b

Ensembl ID : ENSOMYG00000004852
Gene Symbol: CHRM5B
1 Cross references
184 Possible Orthologues:

Cholinergic Receptor, Muscarinic 5b

Ensembl ID : ENSOMYG00000014616
Gene Symbol: CHRM5B
1 Cross references
183 Possible Orthologues:

Coagulation Factor Ii (Thrombin) Receptor

Ensembl ID : ENSOMYG00000022067
Gene Symbol: F2R
2 Cross references
216 Possible Orthologues:

Coagulation Factor Ii Thrombin Receptor

Ensembl ID : ENSOMYG00000068290
Gene Symbol: F2R
1 Cross references
257 Possible Orthologues:

Coagulation Factor Ii Thrombin Receptor

Ensembl ID : ENSOMYG00000003544
Gene Symbol: F2R
1 Cross references
257 Possible Orthologues:

Coagulation Factor Iii, Tissue Factor

Ensembl ID : ENSOMYG00000043189
Gene Symbol: F3
1 Cross references
172 Possible Orthologues:

Coagulation Factor Iiia

Ensembl ID : ENSOMYG00000019166
Gene Symbol: F3A
1 Cross references
192 Possible Orthologues:

Coagulation Factor Iiia

Ensembl ID : ENSOMYG00000018368
Gene Symbol: F3A
1 Cross references
191 Possible Orthologues:

Coagulation Factor Vii, Like

Ensembl ID : ENSOMYG00000050113
Gene Symbol: F7L
1 Cross references
78 Possible Orthologues:

Coagulation Factor X

Ensembl ID : ENSOMYG00000008677
Gene Symbol: F10
1 Cross references
236 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).